NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW – Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totaling 5,154 shares, a decline of 83.1% from the April 30th total of 30,482 shares. Based on an average trading volume of 45,351 shares, the days-to-cover ratio is presently 0.1 days.
NRx Pharmaceuticals Price Performance
NRXPW opened at $0.00 on Thursday. NRx Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.18. The firm’s fifty day simple moving average is $0.01 and its 200 day simple moving average is $0.04.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.
Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why
- Dick’s Sporting Goods Isn’t Done Winning Yet
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
